APOC3

APOC3

A gene on chromosome 11q23.1-q23.2 that encodes apolipoprotein C-III, a very low-density lipoprotein (VLDL) protein that inhibits lipoprotein and hepatic lipases; it is thought to delay catabolism of triglyceride-rich particles.
Mentioned in ?
References in periodicals archive ?
This study will evaluate pharmacokinetic (PK) and pharmacodynamic (PD) markers for MAT9001 and Vascepa in a 28-day crossover study in patients with elevated triglycerides (150 - 499 mg/dL), building on an earlier study showing that, compared to Vascepa, MAT9001 provided significantly greater reductions in PD markers known to be associated with increased risk of cardiovascular disease, including triglycerides, Total cholesterol, VLDL-C, non-HDL-C, ApoC3, and PCSK9, without any meaningful increase in LDL cholesterol.
Matinas BioPharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update
ARO-APOC3 is a subcutaneously administered RNAi therapeutic targeting apolipoprotein C-III (APOC3) currently being developed as a potential treatment for patients with severe hypertriglyceridemia and FCS.
Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-APOC3
The new preclinical data presented on ARO-APOC3 and ARO-ANG3 included the following:: A single 2 mg/kg dose of ARO-APOC3 in ApoC3 transgenic mice led to the following observations: Serum ApoC3 levels were reduced by approximately 90%, maximum knockdown was sustained for over three weeks.
Arrowhead presents preclinical data on expanding cardiometabolic pipeline
Chromosonal SNP array, urine metabolic studies, copper studies, cholesterol studies, 7/8 dehydrocholesterol, creatine kinase, transferrin isoforms, APOC3, and very long chain fatty acids were found to be normal.
Congenital Glaucoma: a Novel Ocular Manifestation of Hajdu-Cheney Syndrome
Expressions of APOC3 (GeneID 345) and APOA5 (GeneID) were upregulated by E2.
Effects of Estrogen and Estrogen Receptors on Transcriptomes of HepG2 Cells: A Preliminary Study Using RNA Sequencing
Rotterdam-based biotech Argenx (EBR: ARGX) reported on Wednesday that preclinical data has been published in Nature Medicine on ARGX-116 inhibiting ApoC3, a metabolic target correlated with blood lipid levels.
Argenx publishes preclinical data on ARGX-116
Many later genetic studies have confirmed these findings, including one of our own demonstrating that APOC3 (apolipoprotein C3) loss-of-function heterozygosity led to lifelong low triglycerides and consequently reduced ischemic cardiovascular disease (2, 6).
A New Start for Triglycerides and Remnant Cholesterol-Nonfasting
La RI hepatica tambien aumentaria la produccion y secrecion de VLDL por aumento de la disponibilidad de apolipoproteina B (apo B) y sintesis de ApoC3 y aumentando la expresion de la proteina de transferencia triglicerido microsomal (MTP).
NAFLD and High Fructose Intake. A Review of Literature/NAFLD e Ingesta de Fructosa en Altas concentraciones. Una Revision de la Literatura
Hypercholesterolemia is associated with the apolipoprotein C-III (APOC3) genotype in children receiving HAART: an eight-year retrospective study.
Dyslipidemia with HIV: high prevalence, multiple risks
Tybjraeg-Hansen, "Loss-of-function mutations in APOC3 and risk of ischemic vascular disease," New England Journal of Medicine, vol.
Apolipoprotein CIII Overexpression-Induced Hypertriglyceridemia Increases Nonalcoholic Fatty Liver Disease in Association with Inflammation and Cell Death
A proximal part of Chr 9 is known to have many genes relevant to lipid metabolism, including Apoa1, Apoc3, Apoa4, Apoa5, and Lipc, and multiple QTL including Cq4, Cq5, and Hdlq17 [17] have been reported.
Identification of Quantitative Trait Loci That Determine Plasma Total-Cholesterol and Triglyceride Concentrations in DDD/Sgn and C57BL/6J Inbred Mice
Caption: Figure 2: Plasma ApoC3 significantly decreased in a dose dependent manner in low OxLA (P < 0.05) compared to plain group.
Dietary Oxidized Linoleic Acid Modulates Plasma Lipids beyond Triglycerides Metabolism

Medical browser ?
Full browser ?